Molecular Neurodegeneration
About the Research Project
Program
Award Type
Standard
Award Amount
$300,000
Active Dates
December 01, 2016 - November 30, 2022
Grant ID
CA2017563
Summary
Molecular Neurodegeneration (MN) is an open access, peer-reviewed journal that encompasses all aspects of neurodegeneration research at the molecular and cellular levels https://molecularneurodegeneration.biomedcentral.com/). The current Editors-In-Chief are Guojun Bu, PhD, Mayo Clinic, USA, and Huaxi Xu, PhD, Sanford Burnham Prebys Medical Discovery Institute, USA. MN is the official journal of the BrightFocus Foundation (http://www.brightfocus.org/research/molecular-neurodegeneration-journal). The open access publishing model provides free articles to the general public, as well as scientists, clinicians, and other healthcare practitioners. MN publishes peer-reviewed, original scientific research on the causes of neurodegenerative diseases, such as Alzheimer’s or Parkinson’ and on the pre-clinical testing of potential therapies for these devastating diseases. In 2016, MN has an impact score of 6.56., meaning the journal is now the highest ranking open access neuroscience journal in the journal citation reports (JCR).
Grants
Related Grants
Alzheimer's Disease Research
Identifying Women-Specific and Men-Specific Risk Factors for Alzheimer’s Disease
Active Dates
July 01, 2022 - June 30, 2024
Principal Investigator
Gael Chetelat, PhD
Identifying Women-Specific and Men-Specific Risk Factors for Alzheimer’s Disease
Active Dates
July 01, 2022 - June 30, 2024
Principal Investigator
Gael Chetelat, PhD
Alzheimer's Disease Research
Mitochondrial Prodrug to Treat Repeated Mild Traumatic Brain Injury
Active Dates
September 08, 2021 - December 31, 2023
Principal Investigator
Patrick Sullivan, PhD
Mitochondrial Prodrug to Treat Repeated Mild Traumatic Brain Injury
Active Dates
September 08, 2021 - December 31, 2023
Principal Investigator
Patrick Sullivan, PhD
Alzheimer's Disease Research
Advancing the Promising Cerebroprotectant AST-004 to Human Clinical Trials
Active Dates
July 02, 2021 - June 30, 2024
Principal Investigator
William Korinek, PhD
Advancing the Promising Cerebroprotectant AST-004 to Human Clinical Trials
Active Dates
July 02, 2021 - June 30, 2024
Principal Investigator
William Korinek, PhD